Donor lymphocyte infusions mediate superior graft-versus-leukemia effects in mixed compared to fully allogeneic chimeras: A critical role for host antigen-presenting cells

Blood

Volumn 100, Issue 5, 2002, Pages 1903-1909

  Mapara, Markus Y ^a,b   Kim, Yong Mi ^a,b   Wang, Sheng Ping ^a,b   Bronson, Roderick ^a,b   Sachs, David H ^a,b   Sykes, Megan ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b TUFTS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOGRAFT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ARTICLE; BONE MARROW TRANSPLANTATION; CHIMERA; CONTROLLED STUDY; FEMALE; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOPOIETIC SYSTEM; LEUKOCYTE; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PRIORITY JOURNAL; T CELL LYMPHOMA;

EID: 0036720416     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-01-0023     Document Type: Article

References (26)

1. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic marrow grafts
2. Antileukemic effect of chronic graft-versus-host disease
3. Graft-versus-leukemia reactions after bone marrow transplantation
4. Graft-versus-host-related immunosuppression is induced in mixed chimeras by alloresponses against either host or donor lymphohematopoietic cells
5. Lymphohematopoietic graft-vs-host reactions can be induced without graft-vs-host disease in murine mixed chimeras established with a cyclophosphamide-based non-myeloablative conditioning regimen
6. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients
7. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients
8. Intentional induction of mixed chimerism and achievement of antitumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies
9. Mixed lymphohaemopoietic chimerism and graft-vs-lymphoma effects after non-myeloablative therapy and HLA-mismatched bone marrow transplantation
10. Induction of stable long-term mixed hematopoietic chimerism following a cyclophosphamide-based non-myeloablative conditioning regimen leads to donor-specific in vitro and in vivo tolerance
11. Effects of T cell depletion in radiation bone marrow chimeras, III: Characterization of allogeneic bone marrow cell populations that increase allogeneic chimerism independently of graft-vs-host disease in mixed marrow recipients
12. Characterization of a monoclonal antibody directed against mouse macrophage and lymphocyte Fc receptors
13. Graft-vs-host and graft-vs-leukemia reactions after delayed infusions of donor T-subsets
14. IL-2 reduces graft-vs-host disease and preserves a graft-vs-leukemia effect by selectively inhibiting CD4+ T cell activity
15. Interleukin-12 preserves the graft-vs-leukemia effect of allogeneic CD8 T cells while inhibiting CD4-dependent graft-vs-host disease in mice
16. Prevention of graft versus host disease by inactivation of host antigen-presenting cells
17. Genetic analysis of the antileukemic effect of mixed allogeneic bone marrow transplantation
18. Adoptive immunotherapy in canine chimeras
19. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: Separation of graft-versus-leukemia responses from graft-versus-host disease
20. Host T cells resist graft-versus-host disease mediated by donor leukocyte infusions
21. Role of immunoregulatory donor T cells in suppression of graft-versus-host disease following donor leukocyte infusion therapy
22. Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides and antileukemia reaction without graft-versus-host disease
23. Delayed infusion of immuno-competent donor cells after bone marrow transplantation breaks graft-host tolerance and allows for persistent antileukemic reactivity without severe graft versus host disease
24. Transplantlite: Induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies
25. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematological diseases
26. Induction of graft-vs-leukemia (GvL) as primary treatment of chronic myelogenous leukemia